Emanuele Gabellieri

Title: Emanuele Gabellieri: Innovator in Pharmaceutical Chemistry

Introduction

Emanuele Gabellieri is a notable inventor based in Siena, Italy, recognized for his contributions to pharmaceutical chemistry. With a total of five patents to his name, Gabellieri has made significant strides in developing compounds that target critical health issues, including Alzheimer's disease and type 2 diabetes.

Latest Patents

One of Gabellieri's latest patents involves 1,4 oxazines as BACE1 and/or BACE2 inhibitors. This invention relates to 1,4 Oxazines of formula I that exhibit BACE1 and/or BACE2 inhibitory activity. The active compounds are designed for therapeutic and/or prophylactic treatment of conditions such as Alzheimer's disease and type 2 diabetes. Another significant patent is for 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds. This invention pertains to compounds that serve as BACE2 inhibitors and can be utilized as medicaments for treating diabetes and other metabolic disorders.

Career Highlights

Gabellieri has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Siena Biotech S.p.a. His work in these organizations has contributed to the advancement of innovative treatments in the medical field.

Collaborations

Gabellieri has collaborated with notable colleagues, including Wolfgang Wostl and Wolfgang Guba, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Emanuele Gabellieri's innovative work in pharmaceutical chemistry has led to the development of important therapeutic compounds. His contributions are vital in addressing significant health challenges, particularly in the fields of Alzheimer's disease and diabetes.